

DT03 Rec'd PCT/PT0 2 2 DEC 2007
|Attorney's Docket Number


CC	ESIGNAT DNCERNI	FAL LETTER TO THE UNITED STATES ED/ELECTED OFFICE (DO/EO/US) NG A FILING UNDER 35 U.S.C. § 371 Unassigned Unassigned United by Detailed Principles						
interna	ational Ap	plication. No. International Filing Date						
F	PCT/EP20	03/006760 June 26, 2003 June 26, 2002						
Title of	f Invention	: CAMPTOTHECIN-CARBOXYLATE FORMULATIONS						
		,						
Applica	ants For E	O/EO/US: Heinrich HAAS, Brita SCHULZE, Uwe MICHAELIS, Michael TEIFEL,						
Birgitta	SAUER,	and Thomas FICHERT						
	licant here er informa	with submits to the United States Designated/Elected Office (DO/EO/US) the following items tion:						
1. 2.	\square	This is a FIRST submission of items concerning a filing under 35 U.S.C. § 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under						
3.		35 U.S.C. § 371. This express request to begin national examination procedures (35 U.S.C. § 371(f)) at any time rather than delay examination until the expiration of the applicable time limit						
4.		set in 35 U.S.C. § 371(b) and PCT Articles 22 and 39(l). A proper Demand for International Preliminary Examination was made by the 19th						
-	F	month from the earliest claimed priority date.						
5.		A copy of the International Application as filed (35 U.S.C. § 371(c)(2)) a.						
		International Bureau).						
		b. is not required, as the application was filed in the United States						
6.	\boxtimes	Receiving Office (RO/US). A copy of the International Application as filed has been transmitted by the						
	-	International Bureau.						
7.		A translation of the International Application into English (35 U.S.C. § 371(c)(2)).						
8.	\boxtimes	Amendments to the claims of the International Application under PCT Article 19						
		(35 U.S.C. § 371(c)(3)). a.						
		International Bureau).						
		b. have been transmitted by the International Bureau.						
		c. have not been made; however, the time limit for making such amendments has NOT expired.						
		d. Anave not been made and will not be made.						
9.		A translation of the amendments to the claims under PCT Article 19 (35 U.S.C.						
10.		§ 371(c)(3)). An eath or declaration of the inventors (25 H S C § 271(c)(4))						
10. An oath or declaration of the inventors (35 U.S.C. § 371(c)(4)). 11. A translation of the annexes to the International Preliminary Examination Report								
		under PCT Article 36 (35 U.S.C. § 371(c)(5)).						
Items 1	2. to 15. b	elow concern other document(s) or information included:						
12.		An Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98.						
13.		An assignment document for recording. A separate cover sheet in compliance with						
14.	37 C.F.R. § 3.28 and § 3.31 is included. A FIRST preliminary amendment.							
14.	A FIRST prefinitially amendment. A SECOND or SUBSEQUENT preliminary amendment.							
15.	Other items or information:							
68 pages of specification, including 3 pages of claims, and 14 pages of								
		Drawings including 14 Figures; Preliminary Amendment; WO 2004/002454 A1 (Cover page only); PCT/RO/101; PCT/ISA/210; International Preliminary Examination Report;						

and Request for the recordal of a change under PCT Rule 92 Bis.

DT05 Rec'd PCT/PT0 2 2 DEC 2004

10/519193

U.S. APPLICATION NO.	INTERNATIONAL	APPLICATION NO.	ATTORNET DOCKET	HUMBER			
unassigned	unassigned PCT/EP2003/006760 062587-5003						
Basic National Fee (37 C.F.R. § 1.492(a)(1)-(5)):							
NATIONAL STAGE BASIC FEE AMOUNT = S							
			tnan	,	!		
20 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(e)).							
	Number Filed 22 - 20 =	Number Extra	<u>Rate</u> X \$50.00		\$ 100.00		
Total Claims	1 - 3 =	0	X \$200.0	\$ 100.00			
Multiple dependent claim(s) (if applicable) + \$360.00 Application Size Fee - \$250.00 for each additional 50 sheets that exceeds 100							
Search Fee	200.00 for each au	ultional 50 sheets th	at exceeds 100	\$500.00	\$		
Examination Fee				\$200.00			
Examination ree		•	TOTAL OF ABOVE C		\$ 1100.00		
TOTAL OF ABOVE CALCULATIONS Reduction by ½ for filing by small entity, if applicable.							
Reduction by 72 for filling by small entity, it applicable.							
SUBTOTAL =							
Processing fee of \$130.0	00 for furnishing the	English translation	later		\$ 550.00		
Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 C.F.R. § 1.492(f)).							
TOTAL NATIONAL FEE =							
Fee for recording the enclosed assignment (37 C.F.R. § 1.21(h)).							
The Assignment must be accompanied by an appropriate cover sheet							
(37 C.F.R. §§ 3.28, 3.31). \$40.00 per property							
TOTAL FEES ENCLOSED =							
Amount to be refunded							
Amount to be charged							
a. A check in the amount of \$ to cover the above fees is enclosed.							
to cover the above fees. A duplicate copy of this sheet is enclosed.							
c. Except for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby							
authorized by this paper to charge any additional fees during the entire pendency of this							
application including fees due under 37 C.F.R. § 1.16 and § 1.17 which may be required,							
or credit any overpayment to Deposit Account No. 50-0310.							
Dalla Time							
Customer No. 09629 Customer No. 09629 Customer No. 09629							
SEND ALL CORRESPONDENCE TO: /Sally P. Teng, Reg. #45,397							
Morgan, Lewis & Bockius LLP 1111 Pennsylvania Avenue, N.W. Date: December 22, 2004							
Washington, D.C. 20004							
Telephone: (202) 739-3000							
Facsimile: (202) 739-3001							
1 accomme. (202) 137-3001							



WEICKMANN & WEICKMANN

Patentanwälte

European Patent Attorneys · European Trademark and Design Attorneys

WEICKMANN & WEICKMANN, Postfach 860 820, 81635 München

Fax and Mail

Organisation Mondiale de la Propriété Intellectuelle Case Postale 18

1211 Genève 20 SCHWEIZ

IHR ZEICHEN / YOUR REF.

UNSER ZEICHEN / OUR REF. 28053P WO/WWbj

DIPL.-ING. H. WEICKMANN (bis 2001)
DIPL.-ING. F. A. WEICKMANN
DIPL.-CHEM. B. HUBER
DR.-ING. H. LISKA
DIPL.-PHYS. DR. J. PRECHTEL
DIPL.-CHEM. DR. B. BÖHM
DIPL.-CHEM. DR. W. WEISS
DIPL.-PHYS. DR. J. TIESMEYER
DIPL.-PHYS. DR. M. HERZOG
DIPL.-PHYS. B. RUTTENSPERGER
DIPL.-PHYS. B. RUTTENSPERGER
DIPL.-PHYS. DR.-ING. V. JORDAN
DIPL.-CHEM. DR. M. DEY
DIPL.-FORSTW. DR. J. LACHNIT
LL.M. DR. U. W. HERBERTH *

DATUM / DATE
Nov 24, 2004

Patentanmeldung Nr. PCT/EP03/06760 Munich Biotech AG

Request for the recordal of a change under PCT Rule 92 bis:

The applicant of the above mentioned international application has changed from Munich Biotech AG

to

MediGene Oncology GmbH Lochhamer Straße 11 82152 Planegg/Martinsried Germany (DE/DE).

Recording of this change is requested herewith.

Dr. W. Weis

Postfach 860 820 81635 München

Kopernikusstraße 9 81679 München

Deutschland

Telefon (089) 45563 0 (0700) WEICKMAN Telefax (089) 45563 999 E-Mail email@weickmann.de Internet www.weickmann.de

Vat-ID, Nr. DE 130 753 315

Hypovereinsbank München Konto 208 401 (BLZ 700 202 70) S.W.I.F.T.-Adresse HYVE DE MM

Postbank München Konto 77 46-804 (BLZ 700 100 80) S.W.I.F.T.-Adresse PBNKDEFF 700